The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC).

被引：9
|
作者：
Jonker, Derek J.
Nott, Louise M.
Yoshino, Takayuki
Li, Chiang
Gill, Shariene
Shapiro, Jeremy David
Ohtsu, Atsushl
Zalcberg, John Raymond
Vickers, Michael M.
Slims, John
Wei, Alice Chia-Chi
Mittmann, Nicole
Magoski, Nadine M.
Murray, Yvonne
Tsobanis, Eric
Tu, Dongsheng
Kerstein, David
O'Callaghan, Christopher J.
机构：
[1] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[2] Royal Hobart Hosp, Hobart, Tas, Australia
[3] Natl Canc Ctr Hosp East, Chiba, Japan
[4] Boston Biomed Inc, Cambridge, MA USA
[5] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[6] Cabrini Hosp, Melbourne, Vic, Australia
[7] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan
[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[9] Tom Baker Canc Clin, Calgary, AB, Canada
[10] NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[11] Toronto Gen Hosp, Toronto, ON, Canada
[12] Sunnybrook Hlth Sci Ctr, HOPE Res Ctr, Toronto, ON M4N 3M5, Canada
[13] NCIC Clin Trials Grp, Kingston, ON, Canada
[14] NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps3660
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3660
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II randomized trial of autologous tumor lysate dendritic cell vaccine (ADC) plus best supportive care (BSC) compared with BSC, in pre-treated advanced colorectal cancer patients.
    Maurel, Joan
    Caballero-Baos, Miguel
    Mila, Jordi
    Tabera, Jaime
    Varea, Sara
    Vilana, Ramon
    Bianchi, Luis
    Arguis, Pedro
    Pineda, Estela
    Carrera, Gemma
    Cuatrecasas, Miriam
    Paez, David
    Martin-Richard, Marta
    Pages, Mario
    Ramon Ayuso, Juan
    Cid, Joan
    Lozano, Miguel
    Garcia-Albeniz, Xabier
    Castells, Antoni
    Vilella, Ramon
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
    Qin, Shukui
    Fang, Weijia
    Ren, ZhengGang
    Shuangyan, Ou
    Lim, Ho Yeong
    Zhang, Feng
    Choi, Hye Jin
    Tong, Jiandong
    Tao, Min
    Xu, Aibing
    Cheng, Ashley Chi Kin
    Lu, Chang-Hsien
    Chiu, Chang-Fang
    Wahid, Mohamed Ibrahim A.
    Kamble, Shital
    Norquist, Josephine M.
    Zhong, Wen Yan
    Li, Chen
    Chen, Zhendong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] The BRIGHTER trial: A phase III randomized double-blind study of BBI608+weekly paclitaxel versus placebo (PBO) plus weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.
    Shah, Manish A.
    Muro, Kei
    Shitara, Kohei
    Tebbutt, Niall C.
    Bang, Yung-Jue
    Lordick, Florian
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Phase IIb randomized trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE)
    Burke, James M.
    Breitbach, Caroline
    Patt, Richard H.
    Lencioni, Riccardo
    Homerin, Michel
    Limacher, Jean-Marc
    Lusky, Monika
    Hickman, Theresa
    Longpre, Lara
    Kirn, David H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Subgroup Analysis of LUX-Lung 1: A Randomized Phase III Trial of Afatinib (BIBW 2992) + Best Supportive Care (BSC) versus Placebo plus BSC in Patients with NSCLC Failing 1-2 Lines of Chemotherapy and Erlotinib or Gefitinib
    Miller, V. A.
    Hirsch, V.
    Cadranel, J.
    Chen, Y.
    Park, K.
    Kim, S.
    Lorence, R.
    Shaidi, M.
    Cong, J.
    Yang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S557 - S558
  • [36] Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment
    Van Cutsem, Eric
    Yoshino, Takayuki
    Hocke, Julia
    Oum'Hamed, Zohra
    Studeny, Matus
    Tabernero, Josep
    CLINICAL COLORECTAL CANCER, 2016, 15 (01) : 91 - 94
  • [37] ISEL: a Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens
    Thatcher, N
    Chang, A
    Parikh, P
    Pemberton, K
    Archer, V
    LUNG CANCER, 2005, 49 : S4 - S4
  • [38] High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17-A phase III trial of cetuximab versus best supportive care (BSC)
    Jonker, D. J.
    Karapetis, C.
    Harbison, C.
    O'Callaghan, C. J.
    Tu, D.
    Simes, R. J.
    Xu, L.
    Moore, M. J.
    Zalcberg, J. R.
    Khambata-Ford, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.
    Ciuleanu, T.
    Samarzjia, M.
    Demidchik, Y.
    Beliakouski, V.
    Rancic, M.
    Bentsion, D. L.
    Orlov, S. V.
    Schaeffier, B. A.
    De Jager, R. L.
    Breitz, H. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] The BRIGHTER trial: A phase III randomized double-blind study of BBI-608+weekly paclitaxel versus placebo (PBC)) plus weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.
    Shah, Manish A.
    Muro, Kei
    Shitara, Kohei
    Tebbutt, Niall C.
    Bang, Yung-Jue
    Lordick, Florian
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345